Media Centre
Latest press releases
-
FDA authorises restart of the COVID-19 AZD1222 vaccine US Phase III trial
-
Farxiga DAPA-CKD Phase III trial reduced worsening of kidney function, risk of cardiovascular or renal death in patients with chronic kidney disease, irrespective of underlying cause
-
AstraZeneca advances leadership in renal disease with more than 80 abstracts at ASN Kidney Week 2020 Reimagined
-
Tagrisso granted Priority Review in the US for the adjuvant treatment of patients with early-stage EGFR-mutated lung cancer
-
Forxiga recommended for approval in the EU by CHMP for heart failure
Medical Releases
These press releases are specifically for health specialist/medical media and are not for consumer press.
Contact us
Email the Global Media Relations team at:
Gonzalo Viña
Head of Global Media Relations
+44 203 749 5916
Rebecca Einhorn
Director Global Media Relations (Oncology)
+1 301 398 1802
Kim Blomley
Director Global Media Relations (Oncology)
+44 7385 367659
Matthew Kent
Director Global Media Relations (BioPharmaceuticals)
+44 203 749 5906
Angela Fiorin
Director Global Media Relations (BioPharmaceuticals)
+44 122 334 4690
Jennifer Hursit
Manager Global Media Relations
+44 203 749 5762
Christina Malmberg Hägerstrand
Media Relations Director, Sweden and Nordic-Baltic
+46 855 253 106
